Pregnancy worsens renal function in females with chronic renal failure (CRF) through an unknown mechanism. Reduced nitric oxide (NO) generation induces renal injury. Arginine transport by cationic amino acid transporter-1 (CAT-1), which governs endothelial NO generation, is reduced in both renal failure and pregnancy. We hypothesize that attenuated maternal glomerular arginine transport promotes renal damage in CRF pregnant rats. In uremic rats, pregnancy induced a significant decrease in glomerular arginine transport and cGMP generation (a measure of NO production) compared with CRF or pregnancy alone and these effects were prevented by L-arginine. While CAT-1 abundance was unchanged in all experimental groups, protein kinase C (PKC)-␣, phosphorylated PKC-␣ (CAT-1 inhibitor), and phosphorylated CAT-1 were significantly augmented in CRF, pregnant, and pregnant CRF animals; phenomena that were prevented by coadministrating L-arginine. ␣-Tocopherol (PKC inhibitor) significantly increased arginine transport in both pregnant and CRF pregnant rats, effects that were attenuated by ex vivo incubation of glomeruli with PMA (a PKC stimulant). Renal histology revealed no differences between all experimental groups. Inulin and p-aminohippurate clearances failed to augment and renal cortical expression of hypoxia inducible factor-1␣ (HIF-1␣) significantly increased in CRF pregnant rat, findings that were prevented by arginine. These studies suggest that in CRF rats, pregnancy induces a profound decrease in glomerular arginine transport, through posttranslational regulation of CAT-1 by PKC-␣, resulting in attenuated NO generation. These events provoke renal damage manifested by upregulation of renal HIF-1␣ and loss of the ability to increase glomerular filtration rate during gestation.
end-stage renal disease; renal damage MATERNAL RENAL FUNCTION may decline as a result of pregnancy among patients with renal disease and this process is determined, in part, by the severity of underlying renal disease. A large number of women with moderate renal insufficiency may have an irreversible decline in glomerular filtration rate that is greater than predicted based on the patient's previous course. Several small studies suggest that as many as one-third experience an irreversible decline and up to 10% progress to end-stage renal disease (12, 13, 15, 16) . The risk of an irreversible decline in renal function may exceed 50% in patients who also have uncontrolled hypertension (16) .
Current recommendations suggest that if functional loss is above 50% stated as a serum creatinine above 1.4 mg/dl, pregnancy can adversely influence the mother's renal prognosis. Therefore, these women are frequently advised to avoid gestation. Endothelial dysfunction is a common denominator of chronic renal failure. Accumulated evidence indicates that endothelial dysfunction is linked to either impaired capacity of the constitutive, Ca 2ϩ /calmodulin-sensitive nitric oxide synthase (NOS) [endothelial NOS (eNOS)] to generate adequate quantities of NO or decreased local NO bioavailability and this plays a role in inducing renal injury (1, 8, 22, 31) . For example, elevated NO production in Wistar-Furth rats was associated with protection from the progression of chronic renal disease after renal mass reduction (8) , and kidney damage was accelerated in eNOS knockout mice following renal ablation while it was improved by administration of L-arginine (22) .
Previous studies suggest that L-arginine, as the sole precursor for NO generation, governs NOS activity (17, 41) . Among several transporters that mediate L-arginine uptake, cationic amino acid transporter-1 (CAT-1) is considered as the predominant arginine supplier for eNOS (21, 30) . Several studies have shown that arginine transport is markedly inhibited in uremia (34, 40, 42) . We recently found that during normal pregnancy, maternal vasculature is subjected to diminished arginine uptake, implying that both renal failure and pregnancy are independently characterized by diminished arginine uptake velocities (28) . Accordingly, the current studies were designed to determine whether the coexistence of pregnancy and renal failure exerts a synergistic deleterious effect on glomerular arginine transport, thus leading to diminished eNOS activity. We also wished to explore whether the aforementioned events worsen renal damage in females with renal failure during gestation.
METHODS

Materials.
All standard reagents were obtained from Sigma unless indicated otherwise. H 3 L-arginine was supplied by Perkin Elmar Life and Analytical Sciences (Boston, MA).
All animal experiments described in this study were conducted in accord with the protocol approved by the institutional committee on ethics in animal experiments. Studies were performed using female Wistar rats at 12-14 wk of age. Subsequently, rats were segregated into seven groups, respectively: group 1: control, sham-operated rats; group 2: chronic renal failure (CRF): rats underwent a two-stage 5/6 nephrectomy (interval of 1 wk). Following the operation, animals were allowed to recover and have free access to a standard rat chow and tap water. All experiments were performed 6 wk following the second operation. Group 3: pregnancy (P): rats destined to become pregnant were housed with a male breeder, in a climate-controlled room with a 12:12-h light-dark schedule. Day 1 of pregnancy was documented by the presence of spermatozoa in the vaginal lavage. Pregnant rats at 14 -18 days of gestation were used for the experimental procedures. Group 4: CRFϩP: rats destined to become pregnant were housed with a male breeder, 4 wk following the second stage nephrectomy. Experimental procedures were performed at 14 -18 days of gestation as in group 3. Group 5: CRF and arginine (CRFϩARG): L-arginine 3% in the drinking water was administered to CRF rats following the second surgery. Group 6: PϩARG: L-arginine as in group 5 was administered to pregnant rats from day 1 of gestation. Group 7: CRFϩPϩARG: L-arginine was given to rats prepared as in group 4.
Renal plasma flow (RBF) and glomerular filtration rate (GFR) were measured by sodium p-aminohippurate (PAH) and inulin, respectively, in all experimental groups, before death, as previously described (32) .
Additional animals were given intraperitoneal injections of ␣-tocopherol, a PKC inhibitor (90 mg/kg body wt every other day), or castor oil as a vehicle, starting from day 1 of pregnancy or for a corresponding length of time in virgin animals. Rats were euthanized using CO 2. Isolation of glomeruli. Kidneys from all experimental groups were harvested, decapsulated, bisected, and the cortex was carefully dissected free. Glomeruli were prepared using a sieving technique as previously described (33) . Briefly, cortices were minced to a fine paste with a razor blade and gently pressed through a 106-m stainless steel sieve. The resulting material was suspended in HEPES buffer (5 mM KCl, 0.9 mM CaCl2, 1 mM MgCl2, 5.6 mM D-glucose, 25 mM HEPES, 140 mM NaCl), at 4°C, pH 7.4. The suspension was forced through a 20-gauge needle to decapsulate the glomeruli and then passed through a 75-m sieve. Glomeruli that were trapped on the sieve were washed and pelleted by centrifugation at 1,000 rpm for 1 min. This was repeated three times. This fraction consisted of more than 95% glomeruli, the majority of which were decapsulated. These isolated glomeruli were used for arginine uptake and cGMP measurements as well as for protein extraction.
L-Arginine uptake by isolated glomeruli. Uptake of radiolabeled L-arginine in the rat glomeruli was measured as previously described (33) . In brief, isolated glomeruli of each experimental group were incubated and shaken for 10 min in HEPES buffer at pH 7.4, 37°C.
]arginine and L-arginine, in a final concentration of 1 mM, were added to a total volume of 2 ml for an additional 1 min. Transport was terminated by rapidly washing the specimen with ice-cold PBS buffer (4 times, 3 ml/tube). The tissue was then dried and solubilized in 1 ml of 0.5% SDS in 0.5 N NaOH. Seven hundred microliters of the lysate were used to monitor radioactivity, by liquid scintillation spectrometry (Betamatic, Kontron). The remaining 300 l were used for protein content determination by the Lowry method (Lowry Assay Kit, Sigma). Results are expressed as means Ϯ SE of at least five different experiments.
Assessment of cGMP generation. cGMP generation was determined by ELISA. Freshly harvested glomeruli were incubated in HEPES buffer with or without N G -nitro-L-arginine methyl ester (L-NAME), in which a phosphodiesterase inhibitor (1 mM 3-isobutyl-1-methyl-xantine) was included to inhibit cGMP degradation. The suspension was then aliquoted (50 l/tube). Each aliquot was shaken at 37°C for 10 min after which they were subjected to Carbamyl Choline (100 mM, from Sigma), a selective eNOS agonist for an additional 2 min. Subsequently, the samples were rapidly frozen and then homogenized in 5% trichloroacetate (TCA) at 4°C. The precipitate was removed by centrifugation (3,000 rpm, 10 min) and TCA was ether extracted. Residual ether was removed by heating the samples for 5 min at 70°C. cGMP was measured by ELISA (R&D Systems). The difference between cGMP generation with and without L-NAME was used as an index of eNOS activity (5) . Each experiment was repeated six times. To examine a possible role of neuronal NOS (nNOS) in the glomerular response to carbamyl choline (CCh), we repeated the above experiments following pretreatment with 7-nitroindazole (7NI), a selective nNOS inhibitor. 7NI was dissolved in DMSO and peanut oil (25/75%) and was administered (25 mg/kg ip body wt) 30 min before the experiments. This dose has been previously shown to exert an antinociceptive activity and affect tubuloglomerular feedback response, both effects related to nNOS activity. Yet it did not affect systemic blood pressure, suggesting selectivity to nNOS (24, 38) .
Protein quantification by Western blotting. Glomerular CAT-1, eNOS, phosphorylated-eNOS, PKC-␣, phosphorylated PKC-␣, and hypoxia inducible factor-1␣ (HIF-1␣) protein expression were determined by immunoblotting. Glomeruli were placed in ice-cold PBS lysis buffer (pH 7.4), containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 4.5 M leupeptin, and 5 M aprotinin; ICN Biomedicals, 0.01% Triton X-100 and 0.1% SDS), and then mechanically homogenized and left on ice for 45 min. Phosphatase inhibitors, sodium fluoride and sodium orthovanadate (1 mM, Santa Cruz Biotechnology), were added to measure phosphorylated proteins. Homogenates were subsequently centrifuged (13,000 rpm for 10 min, at 4°C). Cell lysates were stored in aliquots in Ϫ70°C. A membrane fraction was obtained by adding an equal volume of lysis buffer supplemented by Tween-20 (0.25%). Protein content of each sample was determined by the method of Lowry. Equal amounts of protein (30 g) were prepared in sample buffer (2% SDS, 0.01% bromophenol blue, 25% glycerol, 0.0625 M Tris·HCl, pH 6.8, 5% mercaptoethanol) and analyzed on a 7.5% SDS-PAGE gel and transferred onto Hybond ECL nitrocellulose membranes (Amersham). Following being blocked, membranes were incubated with polyclonal rabbit anti-rat CAT-1 antibodies, 1:500 (synthesized by Dr. O. Leitner, Weizmann Institute, Rehovot, Israel), monoclonal mouse anti-rat PKC-␣, phosphorylated PKC-␣ (p-PKC-␣), eNOS, phosphorylated (SER 1177 ) eNOS, and HIF-1␣ (from Santa Cruz Biotechnology) for 1 h at room temperature, washed, and incubated with secondary horseradish peroxidase-conjugated goat anti-rabbit antibody (1:10,000) in PBS-T for 1 h. Membranes were subsequently washed three times, for 5 min each, in PBS-T. Membranes were then stripped and reprobed with monoclonal anti-␤-actin antibodies as an internal control. The reactive bands corresponding to CAT-1, PKC-␣, p-PKC-␣, eNOS, p-eNOS, and HIF-1 were detected by enhanced chemiluminescence (Kodak X-OMAT AR film) and quantified by densitometry (n ϭ 4 different experiments).
Immunoprecipitation studies. Aliquots of glomerular tissue cell lysate (1 ml) from the different experimental groups were used for immunoprecipitation. Each tissue lysate sample was incubated with 20 l of anti CAT-1 antibodies for 2 h, at 4°C. Optimal antibody concentration was determined by titration. This was followed by addition of 20 l of protein A-agarose (Santa Cruz Biotechnology) and incubation overnight at 4°C on a rotating device. Pellets were collected by centrifugation (3,000 rpm) for 30 s, 4°C. The supernatants were discarded and each pellet was subsequently washed three times with PBS. After the final wash, the pellets were resuspended in 40 l of 2ϫ electrophoresis sample buffer, boiled for 3 min, and subjected to immunoblotting with antibodies against either CAT-1 or the phosphorylated tyrosine residue of CAT-1 (Santa Cruz Biotechnology). Representative results of three separate experiments are shown. To estimate the phosphorylation of CAT-1 in the different groups, the density of bands for CAT-1 and its phosphorylated form on a film were analyzed as above. Results are adjusted for CAT-1 levels and expressed in arbitrary units (means Ϯ SE, n ϭ 3 rats).
Plasma arginine, asymmetric dimethyl arginen, and symmetric dimethyl arginen measurment by high-performance liquid chromatography. Levels of L-arginine, asymmetric dimethyl arginen (ADMA), and symmetric dimethyl arginen (SDMA) in plasma samples were determined by means of high-performance liquid chromatography as previously described with modifications (20) . Samples were collected into EDTA tubes, centrifuged at 4°C, and stored at Ϫ80°C. Before being analyzed, samples (500 l) were combined with homoarginine (250 l) solution (internal standard) and diluted by adding borate buffer (2 ml, 50 mM), pH 8.5. ADMA, SDMA, and arginine were extracted from plasma samples using Supelco LC SCX cation exchange columns at room temperature. The columns were activated with methanol and equilibrated with borate buffer. Arginine, ADMA, and SDMA were eluted with aqueous solution containing 10% NH 4OH and 50% methanol into glass tubes. Eluates were evaporated under air at 60°C, dissolved in 500 l H2O, and centrifuged in spin-x tubes with 0.22-m filter. Standard solutions were prepared by mixing stock solutions of arginine, ADMA, and SDMA combined with homoarginine. Final concentrations of standard solutions were 12.5 M arginine, 12.5 M ADMA, and 12.5 M SDMA. Samples and standards were derivatized in auto-sampler, using freshly prepared orthophthaldialdehyde solution. Separation was carried out using column Lichrocart 250 -4.6 purospnen star RP 18 E (5 m) and guard 4 -4 of the same material. Mobile phase included 25 mM acetate buffer, pH 6.8 with methanol (ratio 62:38); flow 1 ml/min. For detection, Jasco Fluorometer was used. It was set at 340-nm excitation and 455-nm emission. Data were acquired onto EZ chrom data software and peak heights were determined.
Renal histology. Kidneys were fixed in 10% buffered formalin and embedded in paraffin. The paraffin sections were stained with hematoxylin and eosin and evaluated by light microscopy. Morphologic changes in the glomeruli or tubulointerstitial area were scored on a scale of 0 to 5: 0, none of the glomeruli or no tubulointerstitial area was affected by morphologic changes; 1, Ͻ20%; 2, Ͻ40%; 3, Ͻ60%; 4, Ͻ80%; 5, full. In the analysis of glomeruli, scores were assigned for intraglomerular cell proliferation, glomerular thrombosis, and extracapillary cellular proliferation (crescent formation), and the total score was the sum of the three scores. In the analysis of interstitium, scores were assigned for infiltration of mononuclear cells, tubular damage, and interstitial fibrosis, and the total score was the sum of the three scores. Fifty glomeruli per rat were assessed for glomerular damage and at least 20 separate ϫ200 fields per rat were assessed for tubulointerstitial damage.
Statistical analysis. Data are presented as means Ϯ SE. One-way ANOVA was conducted for comparison between groups. Post hoc analysis using LSD algorithm was performed to allocate the source of significance.
RESULTS
To explore a possible effect of gestation on CAT-1 system in uremic rats, glomerular arginine uptake was measured during pregnancy. Glomerular arginine transport in virgin uremic rats was unchanged from controls. Pregnancy resulted in a significant decrease in arginine transport. In pregnant uremic rats, arginine transport was significantly lower, even compared with pregnant healthy animals. The administration of L-arginine completely prevented the decrease in arginine transport observed in pregnant and in uremic pregnant animals, while it had no effect in CRF rats (Fig. 1A) . Serum arginine levels significantly decreased in the pregnant and pregnant uremic rats. The administration of L-arginine resulted in a marked increase in serum arginine concentrations compared with the corresponding untreated experimental groups (Fig. 1B) .
The abundance of glomerular eNOS and phosphorylated eNOS significantly decreased during pregnancy. While eNOS protein content remained unchanged in all other experimental groups, p-eNOS decreased in pregnant rats treated with arginine and increased in uremic rats both treated and untreated (Fig. 2) .
Next, we measured glomerular cGMP generation, following stimulation with CCh, a selective constitutive NOS agonist, with and without the coadministration of L-NAME (NOS inhibitior). We used the difference between these values as an index of constitutive NOS activity (Fig. 3) . eNOS activity was unchanged in uremic virgin and nonuremic pregnant dames, but it was significantly decreased in CRF pregnant rats. L-Arginine administration completely abolished the decrease in cGMP levels exhibited in CRF pregnant rats while it had no effect in pregnant and uremic virgin rats. When the aforementioned studies were repeated following the systemic administration of 7-NI (nNOS antagonist), no differences were found between animals pretreated with 7NI and vehicle in all experimental groups, suggesting that the decrease in glomerolar NO generation derives predominantly from eNOS inhibition (Fig. 3C) .
To determine whether gestation-induced changes in arginine uptake in CRF rats are associated with parallel directional changes in CAT-1, glomerular CAT-1 protein levels were evaluated. CAT-1 protein was identified as ϳ90 kDa. We found that CAT-1 abundance did not differ in all experimental groups (Fig. 4) . Therefore, we searched for a posttranslational effect of pregnancy on CAT-1, in CRF, by looking at PKC-␣. The abundance of the membrane-bound fraction of both PKC-␣ and its activated form, phosphorylated PKC-␣, was significantly augmented in CRF, pregnant, and pregnant CRF animals, a phenomenon that was prevented by the administration of L-arginine (Fig. 5, A-D) . Immunopreciptation studies for phosphorylated CAT-1 demonstrated a significant increase in its signal in CRF, pregnancy, and CRFϩ pregnancy and a significant decrease in the arginine-treated experimental groups (Fig. 5, E-F) .
The administration of ␣-tocopherol resulted in a significant increase in arginine transport both in pregnant and CRF pregnant rats compared with vehicle-treated animals (Fig. 6A) .
Ex vivo incubation of glomeruli with PMA, a potent stimulant of PKC, significantly attenuated the effect of tocopherol on arginine uptake in pregnant and in pregnant uremic rats (Fig. 6B) .
Serum levels of the two endogenous N-dimethylated L-arginine derivatives, L-ADMA and L-SDMA, significantly increased in uremia, an effect which was blunted in pregnancy. Arginine administration had no effect on serum concentrations of neither ADMA nor SDMA (Fig. 7) . The last set of experiments was designed to explore whether the effects of pregnancy on the L-arginine-NO system, in uremic rats, may represent a bridging pathophysiological mechanism between the accelerated decline in renal function in CRF and gestation. Pregnancy resulted in a significant increase in both inulin and PAH clearances (2.6 Ϯ 0.1 and 7.1 Ϯ 0.42 ml/min), while CRF induced a significant decrease compared with controls (0.9 Ϯ 0.08 and 2.25 Ϯ 0.28 vs. 1.9 Ϯ 0.21 and 4.75 Ϯ 0.38 ml/min, respectively, P Ͻ 0.01). Renal hemodynamics in uremic pregnant and CRF rats were similar. The administration of L-arginine to pregnant uremic rats markedly attenuated the decrease in inulin and PAH clearances when compared with control or pregnant animals, while it had no effect in all other experimental groups (Fig. 8) . Evaluation of renal histology revealed no differences between all experimental groups (data not shown). Renal cortex expression of HIF-1␣ was studied, as an index of tissue injury. Protein expression of HIF-1␣ was significantly increased only in the pregnant uremic group, a phenomenon that was prevented by L-arginine administration, while no differences were noted between all other experimental groups (Fig. 9) .
DISCUSSION
The present study demonstrates that in uremic rats, pregnancy induces a profound decline in maternal glomerular arginine uptake, thus leading to a significant decrease in local NO generation. Unexpectedly, we also found, in the current experiments, that arginine transport did not decrease in female rats subjected to 5/6 nephrectomy, in contrast to our findings in male rats. These findings are consistent with data published by our group, showing that old female rats, in contrast to old males, were protected from age-dependent inhibition of arginine transport (35) , supporting the assumption that females are capable of maintaining adequate arginine transport velocities under conditions that were found to adversely affect the arginine-NO system in males. Somehow, this capacity is lost during gestation. One possible explanation is the concomitant decrease in serum arginine concentrations to levels that are substantially lower than the K m of CAT-1 that could be the result of increased consumption by the placenta. Yet, we feel that the mechanism responsible for the aforementioned phenomenon remains elusive and deserves further studies.
Interestingly, we found that in healthy pregnant animals, glomerular NO generation did not increase while both eNOS and phosphorylated eNOS protein contents actually decreased; these phenomena challenge the common notion that renal hyperfiltration during pregnancy is a result of augmented endothelial NO synthesis and indirectly support previous studies by Alexander et al. (2) and recent findings published by Baylis and co-workers (37) who showed that eNOS activity and protein expression are decreased during gestation. In fact, one can argue that our findings should lead to a decrease in NO generation during normal pregnancy. The lack of decline in NO generation may stem from the fact that we looked at glomerular endothelial NO generation rather than the renal vasculature endothelium.
The aforementioned data raise two questions: 1) why the decrease in arginine transport impacts NO generation in the pregnant uremic animals and not in healthy pregnant rats and 2) is this decrease in arginine transport and NO generation responsible for the accelerated decline in kidney function provoked by pregnancy in chronic kidney disease (CKD) females. A simple answer for the first question would be that arginine transport was significantly lower in the pregnant uremic rats than in healthy pregnant animals. Another possibility is that other factors that have been shown to inhibit NOS activity in uremia including: ADMA, advanced glycation end products, oxidative stress, and tetrahydrobiopterin deficiency may have prevented the NO system to adapt to the changes in CAT activity (3, 10, 18, 27, 39) .
As for the second question, previous studies, using a similar experimental model, failed to demonstrate a deleterious effect of pregnancy on kidney function in uremic rats (7) . Also, we could not find any differences between the study groups when looking at renal histology and renal function tests. Nevertheless, CRF and uremic pregnant rats exhibited similar RBF and GFR rates implying that gestation failed to induce an increase in renal hemodynamics in the latter group, an ability that was regained by the administration of arginine. These observations suggest, that although the decrease in arginine transport in our CKD females during gestation does not result in structural changes characteristic of kidney injury, it provokes a functional loss, namely, the ability to augment RBF and GFR during gestation. It should be noted that our studies are limited by the fact that we did not explore the exact glomerular hemodynamic events that were prevented by arginine administration.
Subsequently, due to the paucity of the histological differences between all experimental groups, we chose to study renal HIF-1␣ expression. Increased HIF-1␣ expression has been reported in animal models of CKD (9) and its activation has been implicated in promotion of fibrogenesis and to have a detrimental effect on disease outcome (11) . Furthermore, HIF-1␣ has been shown to modulate disease activity at an early stage before the occurrence of significant hypoxia (19) , and the existing literature suggests that decreased eNOS activity has been associated with upregulation of HIF-1␣ (25, 29) . We found that HIF-1 protein content was increased in pregnant rats with renal failure, and this was completely prevented by the administration of arginine. These findings strengthen our hypothesis that attenuated glomerular arginine transport plays a significant role in accelerating renal injury in CKD females during pregnancy. This is for the first time, to our knowledge, that a mechanism is proposed to explain the accelerated renal injury during gestation in women with CRF.
We tried to elucidate a molecular mechanism to explain our findings. The fact that changes in arginine uptake were not associated with directional changes in CAT-1 protein content strongly supports the hypothesis that these events involve a posttranslational CAT-1 modulation. We previously reported, in four different experimental models characterized by diminished arginine transport, namely, hypercholesterolemia, chronic renal failure, aging in the male rat, and most importantly, pregnancy in normal rats, a posttranslational regulation of CAT-1, which was associated with upregulation of PKC-␣ (14, 28, 34, 36) . Therefore, we decided to focus exclusively at the membrane fraction of PKC-␣, since this is where the interaction between PKC-␣ and CAT-1 occurs. Similar with our previous findings, we found in the current set of experiments a significant elevation in glomerular membrane-bound fraction of PKC-␣ and its activated form phosphorylated PKC-␣, that was accompanied by increased phosphorylation of CAT-1. Treatment with ␣-tocopherol, a PKC inhibitor, prevented the decrease in arginine transport in the uremic pregnant rats, and ex vivo exposure of glomeruli harvested from tocopheroltreated uremic rats to PMA (a PKC stimulant) abolished its beneficial effect. Taken together, these data establish the notion that during gestation in CRF rats, the decrease in arginine transport is primarily derived from PKC-␣ activation. Although, cation should be carried in analyzing the data of protein phosphorylation assays since they were performed in vitro.
Given the fact that intracellular levels of L-arginine far exceed the K m of NOS enzyme, it appears unlikely that the administration of substrate affects cellular NO production. Surprisingly, numerous studies, both in animals and in humans, unequivocally demonstrated beneficial effects of arginine on vascular response in several conditions, including hypercholesterolemia, hypertension, and diabetes. Moreover, even oral feeding of arginine, which only doubles plasma arginine levels, was found to positively affect atherosclerosis development in cholesterol-fed rabbits and in hypertensive rats (6, 26) . This phenomenon, in which arginine supplementation stimulates NO synthesis despite saturating intracellular concentrations, has been termed "the arginine paradox." In the current experiments, the effects of L-arginine on arginine transport velocities and NO generation were accompanied by the prevention of increase in PKC-␣ and p-PKC-␣ protein content. These findings provide a possible explanation for the arginine paradox. We propose that the beneficial effects of arginine administration on the arginine-NO axis are far beyond a mere substrate supply, but rather via an entirely different mechanism, which involves downregulation of signal transduction pathways that inhibit CAT-1 through PKC-␣ activation.
Another mechanism that can potentially interfere with Larginine transport involves the two N-dimethylated L-arginine derivatives: L-ADMA and L-SDMA. CAT proteins transport L-arginine analogs both into and out of cells, resulting in an exchange of cationic amino acids between both sides of the membrane. Thus, these L-arginine analogs do not only compete with L-arginine for transport but are also capable of driving out intracellular L-arginine (4) . During pregnancy, the increase in serum levels of both ADMA and SDMA observed in CRF was prevented, implying that these agents do not contribute to the decrease in arginine transport exhibited in uremic rats during gestation, leaving PKC activation as a sole mechanism proven to modulate CAT-1 during gestation.
To summarize, in CRF rats, a decrease in glomerular arginine transport is aggravated during pregnancy. This leads to attenuated local NO generation with renal injury manifested by upregulation of renal HIF-1␣ and loss of ability to augment GFR during pregnancy.
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